Eli Lilly | LLY - Net Income

Stock Price
1,100.82
Daily Change
97.36 9.70%
Monthly
5.69%
Yearly
30.71%
Q1 Forecast
1,005.21

Eli Lilly reported $5.58B in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
AbbVie USD 186M 752M Sep/2025
Abbott USD 1.78B 132M Dec/2025
ALKERMES USD 82.76M 4.34M Sep/2025
Amgen USD 1.33B 1.88B Dec/2025
AstraZeneca USD 2.53B 83M Sep/2025
Baxter International USD -46M 137M Sep/2025
Biogen USD 466.5M 168.3M Sep/2025
Bristol-Myers Squibb USD 2.2B 891M Sep/2025
Drreddys Laboratories INR 12.1B 2.08B Dec/2025
Eli Lilly USD 5.58B 78M Sep/2025
Gilead Sciences USD 3.05B 1.09B Sep/2025
GlaxoSmithKline GBP 2.01B 570M Sep/2025
Glaxosmithkline GBP 2.71B 1.27B Sep/2025
J&J USD 5.12B 36M Dec/2025
Medtronic USD 1.37B 334M Sep/2025
Merck USD 2.96B 2.82B Dec/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Novartis USD 3.93B 96M Sep/2025
Novartis USD 3.93B 113M Sep/2025
Novo Nordisk DKK 26.5B 2.53B Jun/2025
Perrigo USD 7.5M 15.9M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
Prestige Brands USD 69.13M 7.36M Sep/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
Sanofi EUR -801M 3.6B Dec/2025
Sanofi EUR -801M 3.6B Dec/2025
United Therapeutics USD 338.7M 29.2M Sep/2025
Zoetis USD 721M 3M Sep/2025